M, V.R. et al. 2022. Risk Assessment of Failures in Generic Drug Development and Approval Procedure under Competitive Generic Drug Therapy and Patent Challenge Exclusivities Provided by the United States Food and Drug Administration: Risk assessment of CGT and PC Exclusivity drugs. Acta Marisiensis - Seria Medica. 68, 1 (Mar. 2022). DOI:https://doi.org/10.2478/amma-2022-0004.